NIH's Special Pooled Fund Includes NCI 'Donation' but No NCI Projects

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

BETHESDA, Md--Dr. Harold Varmus, director of the National Institutes of Health, has pooled $13.4 million from the budgets of all of the institutes to fund projects at five of them.

BETHESDA, Md--Dr. Harold Varmus, director of the National Institutesof Health, has pooled $13.4 million from the budgets of all ofthe institutes to fund projects at five of them.

The National Cancer Institute's "donated" share was$2.6 million. This money has to be considered lost because theNCI will not receive any money from the pooled funds

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content